Table 1.
Characteristics of patients prescribed varenicline, n = 70.
| n | (%) | |
|---|---|---|
| Sociodemographic characteristics | ||
| Mean age, years (SD) | 50 | (7.8) |
| Male sex | 38 | 54% |
| Race/ethnicity | ||
| African American | 14 | 20% |
| White, Hispanic | 53 | 76% |
| White, non-Hispanic | 1 | 1.4% |
| Native American | 1 | 1.4% |
| Other | 1 | 1.4% |
| Smoking cessation treatment characteristics | ||
| Other smoking cessation treatment prescribed | 34 | 49% |
| Nicotine replacement therapy | 32 | 46% |
| Bupropion | 11 | 16% |
| Clinical characteristics | ||
| Medical comorbidity | ||
| HIV | 20 | 29% |
| Hepatitis C | 43 | 61% |
| Hypertension | 36 | 51% |
| Hyperlipidemia | 16 | 23% |
| Diabetes | 14 | 20% |
| Asthma/COPD | 32 | 46% |
| Coronary artery disease | 1 | 1.4% |
| Peripheral vascular disease | 6 | 8.6% |
| Cancer | 3 | 4.3% |
| Cervical dysplasia | 4 | 5.7% |
| Psychiatric comorbidity and treatment status | ||
| Any psychiatric illness | 46 | 66% |
| Depression | 37 | 53% |
| Anxiety | 21 | 30% |
| Bipolar disorder | 6 | 8.6% |
| Psychotic disorder | 7 | 10% |
| Receiving onsite psychiatric treatment | 25 | 36% |
| Receiving any psychiatric treatment | 35 | 50% |
| Substance use characteristics | ||
| Median methadone dose, mg (IQR) | 105 | (60, 150) |
| Positive urine toxicology report in prior six months | ||
| Any opiate | 37 | 47% |
| Any cocaine | 27 | 39% |
| Any benzodiazepine | 8 | 11% |
| ≥50% tests positive for opiate | 10 | 14% |
| ≥50% tests positive for cocaine | 13 | 19% |
| ≥50% tests positive for benzodiazepine | 3 | 4.3% |